Schröder FH - Search Results

1

Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.

Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van Der Kwast TT, Schröder FH, Tanke HJ, van Dekken H. Alers JC, et al. Among authors: schroder fh. Am J Pathol. 2001 Feb;158(2):399-406. doi: 10.1016/s0002-9440(10)63983-1. Am J Pathol. 2001. PMID: 11159178 Free PMC article.

2

Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.

Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schröder FH, van der Kwast TH, Bosman FT, van Dekken H. Alers JC, et al. Among authors: schroder fh. Lab Invest. 1997 Nov;77(5):437-48. Lab Invest. 1997. PMID: 9389787

3

Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours.

Alers JC, Krijtenburg PJ, Hop WC, Bolle WA, Schröder FH, van der Kwast TH, Bosman FT, van Dekken H. Alers JC, et al. Among authors: schroder fh. J Pathol. 1998 Jul;185(3):273-83. doi: 10.1002/(SICI)1096-9896(199807)185:3<273::AID-PATH92>3.0.CO;2-8. J Pathol. 1998. PMID: 9771481

4

Prostate cancer detection at low prostate specific antigen.

Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Schröder FH, et al. J Urol. 2000 Mar;163(3):806-12. J Urol. 2000. PMID: 10687982 Clinical Trial.

5

Identification of genetic markers for prostatic cancer progression.

Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schröder FH, van Dekken H. Alers JC, et al. Among authors: schroder fh. Lab Invest. 2000 Jun;80(6):931-42. doi: 10.1038/labinvest.3780096. Lab Invest. 2000. PMID: 10879743 Free article.

6

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Schröder FH, et al. Urology. 2001 Jan;57(1):83-90. doi: 10.1016/s0090-4295(00)00863-3. Urology. 2001. PMID: 11164149 Clinical Trial.

7

Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model.

Vis AN, Hoedemaeker RF, van der Kwast TH, Schröder FH. Vis AN, et al. Among authors: schroder fh. Prostate. 2001 Feb 1;46(2):154-62. doi: 10.1002/1097-0045(20010201)46:2<154::aid-pros1019>3.0.co;2-1. Prostate. 2001. PMID: 11170143 Clinical Trial.

8

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).

Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. Among authors: schroder fh. Prostate. 2001 Jun 1;47(4):252-61. doi: 10.1002/pros.1069. Prostate. 2001. PMID: 11398172 Clinical Trial.

9

Pathologic features of prostate cancer found at population-based screening with a four-year interval.

Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schröder FH. Hoedemaeker RF, et al. Among authors: schroder fh. J Natl Cancer Inst. 2001 Aug 1;93(15):1153-8. doi: 10.1093/jnci/93.15.1153. J Natl Cancer Inst. 2001. PMID: 11481387 Free article. Clinical Trial.

10

Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.

Vis AN, van Rhijn BW, Noordzij MA, Schröder FH, van der Kwast TH. Vis AN, et al. Among authors: schroder fh. J Pathol. 2002 Jun;197(2):148-54. doi: 10.1002/path.1084. J Pathol. 2002. PMID: 12015737

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

606 results

Search Page